Detection of Actionable BCR-ABL1 Kinase Domain (KD) Mutations in Chronic Myeloid Leukemia (CML) Patients with Failure and Warning Response to Tyrosine Kinase Inhibitors (TKIs): Potential Impact of Next-Generation Sequencing (NGS) and Droplet Digital PCR (ddPCR) on Clinical Decision Making

被引：6

作者：

Soverini, Simona ^{[1
]}

Martelli, Margherita ^{[1
]}

Bavaro, Luana ^{[1
]}

De Benedittis, Caterina ^{[1
]}

Iurlo, Alessandra ^{[2
]}

Galimberti, Sara ^{[3
]}

Pregno, Patrizia ^{[4
]}

Bonifacio, Massimiliano ^{[5
]}

Lunghi, Francesca ^{[6
]}

Castagnetti, Fausto ^{[1
]}

Gugliotta, Gabriele ^{[1
]}

Rosti, Gianantonio ^{[1
]}

Tiribelli, Mario ^{[7
]}

Velotta, Vanessa ^{[8
]}

Stagno, Fabio ^{[9
,10
]}

Rossi, Antonella Russo ^{[11
]}

D'Adda, Mariella ^{[12
]}

Barate, Claudia ^{[13
]}

Crugnola, Monica ^{[14
]}

Luciano, Luigiana ^{[15
]}

Laginestra, Maria Antonella ^{[16
]}

Corner, Adam S. ^{[17
]}

Maar, Dianna ^{[17
]}

Percesepe, Antonio ^{[18
]}

Pileri, Stefano ^{[19
]}

Pane, Fabrizio ^{[20
]}

Saglio, Giuseppe ^{[21
]}

Baccarani, Michele ^{[22
]}

Martinelli, Giovanni ^{[23
]}

Cavo, Michele ^{[24
]}

机构：

[1] Univ Bologna, Inst Hematol LeA Seragnoli, Bologna, Italy

[2] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Hematol, Milan, Italy

[3] Univ Pisa, Dept Hematol, Pisa, Italy

[4] Az Osped Univ Citta Salute & Sci, Hematol Unit, Turin, Italy

[5] Univ Verona, Sect Hematol, Dept Med, Verona, Italy

[6] San Raffaele Sci Inst IRCCS, Hematol & Bone Marrow Transplant Unit, Milan, Italy

[7] Univ Udine, Div Hematol & BMT, Dept Med Area, Udine, Italy

[8] ASL Roma2, Rome, Italy

[9] AOU Policlin V Emanuele, Hematol Sect, Catania, Italy

[10] AOU Policlin V Emanuele, BMT Unit, Catania, Italy

[11] Univ Bari, Hematol, Bari, Italy

[12] ASST Spedali Civili Brescia, Dept Hematol, Brescia, Italy

[13] Univ Pisa, Dept Clin & Expt Med, Hematol, Pisa, Italy

[14] Azienda Osped Univ Parma, Div Hematol, Parma, Italy

[15] Univ Naples Federico II, Dept Clin Med & Surg, Naples, Italy

[16] Hematopathol Sect, Dept Expt Diagnost & Specialty Med, Bologna, Italy

[17] Digital Biol Grp, Bio Rad Labs, Peterborough, Cambs, England

[18] Univ Parma, Dept Med & Surg, Med Genet Unit, Parma, Italy

[19] European Inst Oncol, Hematopathol Unit, Milan, Italy

[20] Univ Naples Federico II, Hematol Unit, Naples, Italy

[21] AO Ordine Mauriziano, Div Univ Ematol & Terapie Cellulari, Turin, Italy

[22] St Orsola Hosp, Inst Hematol L&A Seragnoli, Bologna, Italy

[23] IRST IRCCS, Meldola, Italy

[24] Univ Bologna, Inst Hematol L&A Seragnoli, Dept Expt Diagnost & Specialty Med, Bologna, Italy

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-126767

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

661

引用

页数：6

共 33 条

[21] Next-generation sequencing for BCR-ABL1 kinase domain mutations in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position paper
Soverini, Simona
Albano, Francesco
Bassan, Renato
Fabbiano, Francesco
Ferrara, Felicetto
Foa, Robin
Olivieri, Attilio
Rambaldi, Alessandro
Rossi, Giuseppe
Sica, Simona
Specchia, Giorgina
Venditti, Adriano
Barosi, Giovanni
Pane, Fabrizio
CANCER MEDICINE, 2020, 9 (09): : 2960 - 2970
[22] A Novel Droplet Digital PCR Strategy for Rapid and Sensitive Detection of BCR::ABL1 Kinase Domain Mutations Conferring Resistance to Second-Generation Tyrosine Kinase Inhibitors
De Santis, Sara
Monaldi, Cecilia
Martelli, Margherita
Mancini, Manuela
Bruno, Samantha
Castagnetti, Fausto
Gugliotta, Gabriele
Polakova, Katerina Machova
Ernst, Thomas
Maar, Dianna
Corner, Adam
Cavo, Michele
Soverini, Simona
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S289 - S290
[23] Results of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Advanced Chronic Myeloid Leukemia (CML) Patients (pts) Who Failed Tyrosine Kinase Inhibitors (TKIs) after Developing BCR-ABL Kinase Domain (KD) Mutations.
Jabbour, Elias
Cortes, Jorge
de Padua Silva, Leandro
de Lima, Marcos
Jones, Dan
O'Brien, Susan
Rondon, Gabriela
Popat, Uday
Giralt, Sergio
Kantarjian, Hagop
Champlin, Richard
BLOOD, 2008, 112 (11) : 358 - 358
[24] Ultra-Deep Next-Generation Sequencing (NGS) Detects BCR-ABL1 Kinase Domain Mutations with High Sensitivity and Allows to Monitor the Composition of Distinct Subclones During Tyrosine Kinase Inhibitor Treatment.
Grossmann, Vera
Wild, Melanie
Schnittger, Susanne
Kern, Wolfgang
Haferlach, Torsten
Haferlach, Claudia
Kohlmann, Alexander
BLOOD, 2010, 116 (21) : 933 - 933
[25] Event-free survival in patients (pts) with chronic myeloid leukemia (CML) treated with 2nd generation tyrosine kinase inhibitors (TKI) after imatinib failure is dependent on the in vitro sensitivity of BCR-ABL kinase domain (KD) mutations
Jabbour, Elias
Kantarjian, Hagop
Jones, Dan
Tam, Constantine
Koller, Charles
Borthakur, Gautam
Wierda, William
Cortes, Jorge
BLOOD, 2007, 110 (11) : 577A - 577A
[26] Novel Illumina-based next generation sequencing approach with one-round amplification provides early and reliable detection of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia
Romzova, Marianna
Smitalova, Dagmar
Tom, Nikola
Jurcek, Tomas
Culen, Martin
Zackova, Daniela
Mayer, Jiri
Racil, Zdenek
BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (03) : 469 - 474
[27] Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations
Jabbour, Elias
Jones, Daniel
Kantarjian, Hagop M.
O'Brien, Susan
Tam, Constantine
Koller, Charles
Burger, Jan A.
Borthakur, Gautam
Wierda, William G.
Cortes, Jorge
BLOOD, 2009, 114 (10) : 2037 - 2043
[28] CLINICAL SIGNIFICANCE OF COMBINING BCR-ABL1 TRANSCRIPT LEVELS AT 3 AND 6 MONTHS IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH FRONTLINE SECOND-GENERATION TYROSINE KINASE INHIBITORS
Lee, S. E.
Choi, S. Y.
Kim, S. H.
Oh, Y. J.
Chae, M. J.
Song, H. Y.
Yoo, H. L.
Lee, M. Y.
Jang, E. J.
Jeong, K. H.
Lee, J. S.
Kim, D. W.
HAEMATOLOGICA, 2014, 99 : 599 - 599
[29] In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants
Soverini, Simona
De Benedittis, Caterina
Castagnetti, Fausto
Gugliotta, Gabriele
Mancini, Manuela
Bavaro, Luana
Polakova, Katerina Machova
Linhartova, Jana
Iurlo, Alessandra
Russo, Domenico
Pane, Fabrizio
Saglio, Giuseppe
Rosti, Gianantonio
Cavo, Michele
Baccarani, Michele
Martinelli, Giovanni
BMC CANCER, 2016, 16
[30] In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants
Simona Soverini
Caterina De Benedittis
Fausto Castagnetti
Gabriele Gugliotta
Manuela Mancini
Luana Bavaro
Katerina Machova Polakova
Jana Linhartova
Alessandra Iurlo
Domenico Russo
Fabrizio Pane
Giuseppe Saglio
Gianantonio Rosti
Michele Cavo
Michele Baccarani
Giovanni Martinelli
BMC Cancer, 16

← 1 2 3 4 →